In this issue:
Ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis
Drug survival of adalimumab, ustekinumab and secukinumab in psoriasis
Secukinumab effects on aortic vascular inflammation in plaque psoriasis
Real-world evidence on dupilumab use for atopic dermatitis
Correlates of long-term dupilumab effectiveness in atopic dermatitis
Recommendations for biologics and systemic therapies during COVID-19
Routine laboratory parameter dynamics with anti-TNF and IL-inhibitors
Anti-TNF effect on risk of respiratory tract infections
Adalimumab for active pyoderma gangrenosum ulcers
Avelumab in Merkel cell and squamous cell carcinoma
Please login below to download this issue (PDF)